When David Fajgenbaum nearly died of Castleman disease for the fifth time, he decided to take fate into his own hands. Using his medical training, he searched for an existing drug that might save his life—and found one. Now his organization, Every Cure, is scaling the same approach to uncover hidden treatments for other diseases with no known cure.

David and Claudia discussed: 

• How Every Cure is using AI to test 75 million possible disease-drug combinations 
• The perverse incentives that keep generic drug repurposing in the shadows
• Why the hardest part of innovation isn’t discovery, it’s getting proven treatments into clinical practice

Repurposing existing drugs makes so much sense. But as David points out, there’s no market for it:

“Once a drug is generic.. the price is going to plummet… And even if you were to double the sales of your drug because you found a new disease area, now you've gone from 1% to 2% of what you got before… So there's no incentive whatsoever for our system to find a new use for a generic drug. Zero incentive.”

Relevant Links

• Learn more about Every Cure
• Read David’s book Chasing My Cure: A Doctor’s Race to Turn Hope Into Action
• Watch David's TEDTalk 
• Listen to David’s Podcast interview with Adam Grant
• Get info on the Dada2 Foundation
• Watch a video on Matt Might’s story 

About Our Guest

David Fajgenbaum, MD, MBA, MSc, is co-Founder & President of Every Cure and a physician-scientist at the University of Pennsylvania, where he is one of the youngest faculty members ever to receive tenure at Penn Medicine. He is also the national bestselling author of Chasing My Cure: A Doctor’s Race to Turn Hope Into Action, which is being adapted into a film by Forrest Gump producer Wendy Finerman. 

During medical school, Fajgenbaum discovered a treatment that saved his own life and founded the Castleman Disease Collaborative Network. He has advanced 13 more repurposed treatments for cancers and rare diseases and co-founded Every Cure to unlock more hidden cures from existing medicines which has received over $100M from ARPA-H and TED’s Audacious Project. He also serves on the Board of Directors for the Reagan-Udall Foundation for the FDA. 

One of the youngest recipients of multiple top NIH and FDA grants, Fajgenbaum has authored over 100 scientific papers in leading journals, including The New England Journal of Medicine, The Lancet, and The Journal of Clinical Investigation. He has been profiled by The New York Times, Good Morning America, TODAY, and Forbes 30 Under 30 and has received numerous honors, including the 2016 Atlas Award alongside then VP Joe Biden, 2022 NDRI Service to Science Award alongside Nobel Laureates Katalin Kariko and Drew Weissman, 2023 Philadelphia Citizen of the Year Award, and selection to the 2025 TIME100 Health list of the world’s most influential people in health. Fajgenbaum earned a BS from Georgetown University, MSc from the University of Oxford, MD from the University of Pennsylvania, and MBA from The Wharton School.

Source

Connect With Us

For more information on The Other 80 please visit our website - www.theother80.com. To connect with our team, please email [email protected] and follow us on twitter @claudiawilliams and LinkedIn

Subscribe to The Other 80 on YouTube so you never miss our video extras or special video episodes!